Hepion Pharmaceuticals Finalizes CEO Separation Agreement, Discloses $255K Payout Amidst Going Concern Warning
HEPA sits 45% above its 52-week low of $0.033.
Summary
Hepion Pharmaceuticals, Inc. entered into a separation agreement with its former CEO, Dr. Kaouthar Lbiati, involving a total payout of $255,625 plus COBRA reimbursements, further impacting the company's critical cash position.
Key Events · Executive and Board Changes · HEPA
-
Former CEO Separation Terms Finalized
The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati, including a $225,000 payment and a $30,625 pro-rata cash bonus, totaling $255,625, plus 6 months of COBRA reimbursements.
-
Director Resignation Confirmed
Dr. Lbiati also formally resigned as a director of the company on April 13, 2026, following her prior resignation as CEO.
-
Significant Cash Outflow Amidst Financial Distress
The $255,625 payout represents a substantial portion of the company's market capitalization and further strains its limited cash reserves, which are projected to run out by Q3 2026, as previously disclosed in its going concern warning.
Analysis · HEPA · Life Sciences
This filing details the financial terms of the former CEO's separation, which includes a significant payout of over $255,000. For a company with a market capitalization of approximately $550,000 and a previously disclosed "going concern" warning with cash expected to run out by Q3 2026, this cash outflow is highly material and exacerbates its financial distress. Investors should view this as a further depletion of critical resources for a company already struggling with liquidity and delisting.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HEPA was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $557.8K. The 52-week trading range was $0.03 to $0.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.